Mikiko Takikita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mikiko Takikita has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Carol Giffen
Information Management Services, Inc., Silver Spring, Bethesda, MD 20904, USA
1 shared publication Eiji Takeuchi
Department of Pathology, Shiga Medical Center for Adults, Moriyama 524-8524, Japan
1 shared publication- Jian-Zhong Shou
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China
1 shared publication Kazumasa Ogasawara
Department of Pathology, Shiga University of Medical Science, Otsu 520-2192, Japan
1 shared publicationKoichi Mukai
Department of Pathology, Shiga Medical Center for Adults, Moriyama 524-8524, Japan
1 shared publication- Nan Hu
Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Bethesda, MD 20892, USA
1 shared publication
Latest Publications
- Open Access
- 3 September 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 310
Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma
Background: Cancer of the esophagus is a deadly malignancy, and development of biomarkers that predict survival is an urgent need. The apoptotic pathways have been hypothesized as important in progression of esophageal squamous cell carcinoma (ESCC). We investigated a panel of proteins that regulate apoptosis as candidate of biomarkers of prognosis in ESCC. Methods: Tissue microarray (TMA) including 313 surgically-resected cases of ESCC specimens was built for immunohistochemical interrogation. We evaluated seven genes in the FasL-Fas apoptotic pathway - FasL, Fas, FAS-associated death domain protein (FADD), phosphorylated-FADD, and caspase 8 and 10, and the antiapoptotic protein bcl-2. We studied pathway integrity and relations to risk and clinical factors, and determined the prognostic significance of each marker. Results: Five markers showed strong inter-marker correlations (r ≥ 0.28, p < 0.001), including FasL, Fas, FADD, and caspases 8 and 10. FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases. Multivariate-adjusted proportional hazard regression models showed no association between protein expression and risk of death for any of the seven markers examined. Conclusion: Individual biomarkers in the apoptosis pathway do not appear to predict survival of patients with ESCC.
- 3 September 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 310
Open AccessBiomarkers of apoptosis and survival in esophageal squamous cell carcinoma
Background: Cancer of the esophagus is a deadly malignancy, and development of biomarkers that predict survival is an urgent need. The apoptotic pathways have been hypothesized as important in progression of esophageal squamous cell carcinoma (ESCC). We investigated a panel of proteins that regulate apoptosis as candidate of biomarkers of prognosis in ESCC. Methods: Tissue microarray (TMA) including 313 surgically-resected cases of ESCC specimens was built for immunohistochemical interrogation. We evaluated seven genes in the FasL-Fas apoptotic pathway - FasL, Fas, FAS-associated death domain protein (FADD), phosphorylated-FADD, and caspase 8 and 10, and the antiapoptotic protein bcl-2. We studied pathway integrity and relations to risk and clinical factors, and determined the prognostic significance of each marker. Results: Five markers showed strong inter-marker correlations (r ≥ 0.28, p < 0.001), including FasL, Fas, FADD, and caspases 8 and 10. FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases. Multivariate-adjusted proportional hazard regression models showed no association between protein expression and risk of death for any of the seven markers examined. Conclusion: Individual biomarkers in the apoptosis pathway do not appear to predict survival of patients with ESCC.
- 7 February 2006
- Published by Elsevier in Human Pathology
- Vol. 37 (4) , 493-497
A case of multifocal fibrosclerosis with intracardiac solid masses
- 7 February 2006
- Published by Elsevier in Human Pathology
- Vol. 37 (4) , 493-497
A case of multifocal fibrosclerosis with intracardiac solid masses